News Archive

Our Strategic Partner, Curium Announces ECLIPSE Trial has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer（Curiumu）